Trial ID or NCT#

NCT00725387

Status

not recruiting iconNOT RECRUITING

Purpose

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Official Title

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Andrei Iagaru
Andrei Iagaru
Radiologist
Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center
Sandip Biswal, MD
Sandip Biswal, MD
Radiologist
Associate Professor of Radiology (Musculoskeletal Imaging) at the Stanford University Medical Center
Sanjiv Sam Gambhir, MD, PhD
Amelie Lutz
Amelie Lutz
Diagnostic radiologist, Radiologist
Assistant Professor of Radiology (Musculoskeletal Imaging) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Andrei Iagaru
(650) 736-2859